IVERIC bio (ISEE) Announces $125M Stock Offering
- Wall Street rebounds after virus-related sell-off
- Here's What Analysts are Saying as Twitter (TWTR) Stock Erases Earlier Gains
- Moderna (MRNA) Stock Up 10% as WHO Says Omicron Covid Variant Poses 'Very High' Global RIsk
- 2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch
- Why EV Li Auto (LI) Stock Is Up 8% Today
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $125.0 million of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock being offered. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares are to be offered by the Company.
Morgan Stanley, Cowen, Stifel and Credit Suisse are acting as the book-running managers for the offering.
An automatically effective shelf registration statement on Form S-3 relating to the shares of common stock to be offered was filed with the Securities and Exchange Commission (the “SEC”) on October 21, 2021. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to the offering is being filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained by contacting: Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department, or by telephone: 1-866-718-1649; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by emailing PostSaleManualRequests@broadridge.com, or by telephone: (833) 297-2926; Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Prospectus Department, or by emailing firstname.lastname@example.org, or by telephone: (415) 364-2720; or Credit Suisse Securities (USA) LLC, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, Attn: Prospectus Department, or by emailing email@example.com, or by telephone: (800) 221-1037.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualigen Therapeutics (QLGN) Announces $8.82M Registered Direct Common Stock Offering
- Sigilon Therapeutics (SGTX) Announces SIG-001 Trial is Placed on Clinical Hold
- Weibo (WB) Commences Global 11M Share Offering
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings, FDA
Related EntitiesCredit Suisse, Stifel, Morgan Stanley, Cowen & Co, S3
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!